Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Apr 29, 2024 5:55pm
212 Views
Post# 36013588

RE:RE:RE:RE:RE:RE:RE:RE:A move all Oncy shareholders need to make, to screw the shor

RE:RE:RE:RE:RE:RE:RE:RE:A move all Oncy shareholders need to make, to screw the shorAssuming a buyout of $5 billion. Which is on record by all analysts as one years income, very possible. $5 billion buyout would be $60/ ps. The upper end? Depends on how things progress within the next few trial updates. Lower end..? They have said many times $1 billion is a minimum staring point. That was long before the recent biotech market place activities. Again acquisition of much less than the Two phase 3 FDA fast track approved. With Roche- tecentriq cotherapy. That being muc( less than that & paying well over $10 billion. I agree 100% Onc is not Apple. However I remember quite clearly you could buy apple shares for $1. Todays share price of any company, has no bearing what so ever of future share price. I get a kick out of the fools who bought into Trumps IPO He needed money to fund his criminal trials & he reached out to his supporters. Im not political. Being Canadian cant vote If I could what a disaste4 you guys have. Trump is on trial on multiple fronts , being supported by anyone he can con. Biden regardless of policies is too old for the job. Back to Onc & I apologize for getting of topic. Any company @ any time can have a paradigm shift & see both rapid decline or rapid acceleration of share price.. Getting Pelareorep into phase 3 with a partner , would be a paradigm shift. Be careful with any company SP. Best opportunities are the ones beaten down with huge upside. Worst opportunities, high flying dream companies. I could fill pages with examples, both sides of the argument. One could debate either way. What matters as an onc investor, which I am. Can Onc get Pela approved for Market? They need further studies & as of two weeks ago, approached FDA with s proposal. The pancreatic trials are increasing enrolment. Know it is written clearly that would only happen with positive data to that point.. So for what I can see, oncolyitics biotech has ample room to initiate the needed paradigm shift. Imho the upside opportunity is far greater than the downside.
<< Previous
Bullboard Posts
Next >>